WO2009071094A3 - Combination treatment of ischemic effects - Google Patents

Combination treatment of ischemic effects Download PDF

Info

Publication number
WO2009071094A3
WO2009071094A3 PCT/DK2008/050292 DK2008050292W WO2009071094A3 WO 2009071094 A3 WO2009071094 A3 WO 2009071094A3 DK 2008050292 W DK2008050292 W DK 2008050292W WO 2009071094 A3 WO2009071094 A3 WO 2009071094A3
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
receptor agonists
binding
reaching
vanilloid
Prior art date
Application number
PCT/DK2008/050292
Other languages
French (fr)
Other versions
WO2009071094A2 (en
Inventor
Jacob Gotfredsen
Uno Jakob Weber
Original Assignee
Neurokey As
Jacob Gotfredsen
Uno Jakob Weber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurokey As, Jacob Gotfredsen, Uno Jakob Weber filed Critical Neurokey As
Publication of WO2009071094A2 publication Critical patent/WO2009071094A2/en
Publication of WO2009071094A3 publication Critical patent/WO2009071094A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to the induction of hypothermia in humans, male and female, at any age, in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a combination of two or more compounds selected among (1) vanilloid receptor agonists, capsaicinoids or capsaicinoid-like agonists reaching and binding to vanilloid receptors, and (2) cannabinoids or cannabimimetic agonists reaching and binding to cannabinoid receptors, and (3) adenosine receptor agonists, and (4) neurotensin receptor agonists, and (5) thyroxine derivatives, and (6) cytochrome c inhibitors, and (7) oxygen tension reducers, with the proviso that if the first compound is (1) then the second is not (2), thereby inducing hypothermia, thus benefiting patients suffering from illnesses characterized by tissue anoxia.
PCT/DK2008/050292 2007-12-05 2008-12-05 Combination treatment of ischemic effects WO2009071094A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200701742 2007-12-05
DKPA200701742 2007-12-05
DKPA200801079 2008-08-07
DKPA200801079 2008-08-07
DKPA200801105 2008-08-15
DKPA200801105 2008-08-15

Publications (2)

Publication Number Publication Date
WO2009071094A2 WO2009071094A2 (en) 2009-06-11
WO2009071094A3 true WO2009071094A3 (en) 2009-08-06

Family

ID=40677642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050292 WO2009071094A2 (en) 2007-12-05 2008-12-05 Combination treatment of ischemic effects

Country Status (1)

Country Link
WO (1) WO2009071094A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155300A1 (en) 2007-04-05 2010-02-24 Velomedix, Inc Automated therapy system and method
CA2693774A1 (en) 2007-07-09 2009-01-15 Velomedix, Inc. Hypothermia devices and methods
WO2012006625A2 (en) 2010-07-09 2012-01-12 Velomedix, Inc. Method and apparatus for pressure measurement
ES2675215T3 (en) 2013-02-08 2018-07-09 General Mills, Inc. Sodium Reduced Food Products
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
WO2018236957A1 (en) * 2017-06-20 2018-12-27 Nexien Biopharma, Inc. Method and compositions for treating restless legs syndrome

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102368A1 (en) * 2002-11-27 2004-05-27 Katz Laurence M. Methods of treating cerebral ischemia
WO2007082309A2 (en) * 2006-01-16 2007-07-19 The Board Of Regents Of The University Of Texas System Adenosine monophosphate for inducing torpor in a subject
WO2008040361A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of a combination of hypothermia inducing drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102368A1 (en) * 2002-11-27 2004-05-27 Katz Laurence M. Methods of treating cerebral ischemia
WO2007082309A2 (en) * 2006-01-16 2007-07-19 The Board Of Regents Of The University Of Texas System Adenosine monophosphate for inducing torpor in a subject
WO2008040361A2 (en) * 2006-10-04 2008-04-10 Neurokey A/S Use of a combination of hypothermia inducing drugs

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
APPENDINO G ET AL: "TRPV1 (vanilloid receptor, capsaicin receptor) agonists and antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 13, no. 12, 1 December 2003 (2003-12-01), pages 1825 - 1837, XP002487646, ISSN: 1354-3776 *
BONFILS P K ET AL: "Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia", NEUROCHEMISTRY INTERNATIONAL, PERGAMON PRESS, OXFORD, GB, vol. 49, no. 5, 1 October 2006 (2006-10-01), pages 508 - 518, XP025067906, ISSN: 0197-0186, [retrieved on 20061001] *
DING ET AL: "Capsaicin evokes hypothermia independent of cannabinoid CB1 and CB2 receptors", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 1065, no. 1-2, 14 December 2005 (2005-12-14), pages 147 - 151, XP005206563, ISSN: 0006-8993 *
DOYLE KRISTIAN P ET AL: "Novel thyroxine derivatives, thyronamine and 3-iodothyronamine, induce transient hypothermia and marked neuroprotection against stroke injury", STROKE, vol. 38, no. 9, September 2007 (2007-09-01), pages 2569 - 2576, XP002531101, ISSN: 0039-2499 *
LEKER RONEN R ET AL: "Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210", STROKE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 34, no. 8, 1 August 2003 (2003-08-01), pages 2000 - 2006, XP002451424, ISSN: 0039-2499 *
PEGORINI S ET AL: "Capsaicin exhibits neuroprotective effects in a model of transient global cerebral ischemia in Mongolian gerbils", BRITISH JOURNAL OF PHARMACOLOGY, NATURE PUBLISHING GROUP, BASINGSTOKE, HANTS, vol. 144, 1 January 2005 (2005-01-01), pages 727 - 735, XP007904383, ISSN: 0007-1188 *
RAWLS S M ET AL: "CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalen yl-carbonyl) -6H-pyrrolo[3,2,1 ij]quinolin-6-one]-induced hypothermia", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 301, no. 3, 1 January 2002 (2002-01-01), pages 963 - 968, XP002451426, ISSN: 0022-3565 *
SZABÓ CSABA: "Hydrogen sulphide and its therapeutic potential.", NATURE REVIEWS. DRUG DISCOVERY NOV 2007, vol. 6, no. 11, November 2007 (2007-11-01), pages 917 - 935, XP002531102, ISSN: 1474-1784 *
TORUP L ET AL: "PHARMACOLOGICALLY INDUCED HYPOTHERMIA REDUCES INFARCT SIZE IN PERMANENT FOCAL ISCHEMIA", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, 1 January 2002 (2002-01-01), pages Abstr.491.9, XP009097719, ISSN: 0190-5295 *
VOLPATO GIAN PAOLO ET AL: "Cardiovascular changes after exposure to hydrogen sulfide in a murine model", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 114, no. Suppl 18, 1 October 2006 (2006-10-01), pages 465, XP009097101, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2009071094A2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
WO2010015260A3 (en) Administration by infusion for the treatment of ischemic effects
WO2008040361A3 (en) Use of a combination of hypothermia inducing drugs
MX2009003469A (en) Use of hypothermia inducing drugs to treat ischemia.
WO2009124552A3 (en) Use of a combination of hypothermia inducing drugs
WO2009071094A3 (en) Combination treatment of ischemic effects
MY148496A (en) Dpp iv inhibitor formulations
CL2013003816A1 (en) Compounds derived from carboxamide and urea comprising aromatic substituted pyrazole, vanilloid receptor binders; pharmaceutical composition that includes them; and its use in the treatment and / or prophylaxis of pain, migraine, parkinson's disease, gastrointestinal disorders, osteoporosis, among other diseases.
WO2009071096A3 (en) Combination of medical and physical cooling treatment of ischemic effects
MA33220B1 (en) Pharmaceutical composition of anti-inflammatory
EA201071039A1 (en) NEW DERIVATIVES 1-BENZYL-3-HYDROXYMETYLINDASOL AND THEIR APPLICATION FOR THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 And P40
MX2020012800A (en) Cannabinoids and uses thereof.
IL168308A (en) Compositions containing roflumilast and formoterol
GT200500268A (en) INHIBITORS OF THE SOLUBLE CYCLING ADENYLATE
ZA200904704B (en) Treatment of cachexia
RS20060344A (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
CO5690571A2 (en) SYNERGIC COMBINATION INCLUDING ROFLUMILAS AND (R, R) -FORMOTEROL
PT1220676E (en) PREVENTION OF COLORCECTAL CANCER
ECSP099730A (en) NEW DERIVATIVES OF 4,8-DIFENIL-POLIAZANAFTALENO
PA8800301A1 (en) CRYSTAL CHEMOTHERAPEUTIC PRODUCTS
WO2009124551A3 (en) Use of vanilloid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
BR0214776A (en) Combination of a selective pde4 inhibitor and a beta-2 adrenergic receptor agonist
DK1389122T3 (en) Epithelial cancer prevention
BRPI0500726A (en) Leishmaniasis vaccine compositions and uses
MD3145G2 (en) Disinfectant remedy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857037

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 14.09.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08857037

Country of ref document: EP

Kind code of ref document: A2